Singapore markets close in 55 minutes

UroGen Pharma Ltd. (0XOD.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
17.96-1.91 (-9.59%)
As of 06:47PM GMT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.06
52-week change 377.12%
S&P500 52-week change 325.48%
52-week high 324.01
52-week low 30.00
50-day moving average 314.81
200-day moving average 314.29

Share statistics

Avg vol (3-month) 3587
Avg vol (10-day) 3594
Shares outstanding 516.1M
Implied shares outstanding 6N/A
Float 819.53M
% held by insiders 18.15%
% held by institutions 177.80%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin -136.00%
Operating margin (ttm)-64.74%

Management effectiveness

Return on assets (ttm)-27.63%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)77.28M
Revenue per share (ttm)3.03
Quarterly revenue growth (yoy)29.50%
Gross profit (ttm)N/A
EBITDA -70.36M
Net income avi to common (ttm)-105.1M
Diluted EPS (ttm)-5.05
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)147.42M
Total cash per share (mrq)4.78
Total debt (mrq)100.4M
Total debt/equity (mrq)N/A
Current ratio (mrq)7.06
Book value per share (mrq)-1.36

Cash flow statement

Operating cash flow (ttm)-85.13M
Levered free cash flow (ttm)-43.29M